Medicare can now cover Eli Lilly's Zepbound for sleep apnea, CMS says
Portfolio Pulse from
Medicare drug plans can now cover Eli Lilly's Zepbound for obstructive sleep apnea, as confirmed by the Centers for Medicare & Medicaid Services. This development could lead to broader coverage and access to Zepbound, which is not widely covered for weight loss.
January 08, 2025 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's Zepbound, a drug for obstructive sleep apnea, is now covered by Medicare, potentially increasing its market reach and sales.
The inclusion of Zepbound in Medicare coverage for sleep apnea can significantly increase its accessibility and sales, as Medicare coverage often leads to broader insurance adoption. This is a positive development for Eli Lilly, likely boosting its stock price.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90